10 months ago
The NxThera acquisition establishes Boston Scientific as the leader in the treatment of symptomatic benign prostatic hyperplasia (BPH) and the only urology partner to offer BPH solutions, education and clinical evidence to empower physicians to effectively treat patients at every stage of their journey. Watch this brief video featuring Kevin McVary, MD, FACS, Co-Chairman of the AUA BPH Clinical Guidelines Committee. He is currently and has recently been principal investigator for more than 75 clinical trials, including the Rezūm pivotal trial.
Learn more: http://www.bostonscientific...
©2018 Boston Scientific Corporation or its affiliates. All rights reserved.